Clinical Research Associates Llc
EIN 463285474Total Given 2017–2024
$1.9M
20 grants · $235K avg/year
based on 8 yrs of IRS 990-PF records on file
$100K+/yr
local funder
capacity
$76K
typical mid grants · $56K–$131K
grant size
50%
supporter · 6/12 multi-year
repeat
$1.4M
Assets (2024)
12
Distinct Recipients
Focus Areas
Application Information
Accepts Unsolicited Proposals
No — Preselected Only
Phone
(646) 654-0066
Financial Trends
Giving Over Time
Total Assets Over Time
View financial data as table
| Year | Total Giving | Total Assets | Revenue | Grants |
|---|---|---|---|---|
| 2017 | $1.1M | $1.0M | $2.1M | 12 |
| 2018 | $282K | $1.2M | $1.7M | 4 |
| 2019 | N/A | $1.4M | $3.2M | N/A |
| 2020 | $232K | $669K | $1.4M | 2 |
| 2021 | $45K | $606K | $1.6M | 1 |
| 2022 | N/A | $2.3M | $3.2M | N/A |
| 2023 | N/A | $1.4M | $3.1M | N/A |
| 2024 | $200K | $1.4M | $4.2M | 1 |
Grant Size Distribution
Based on 20 grants on record
Minimum
$18K
25th Pctl
$56K
Median
$76K
Average
$94K
75th Pctl
$131K
Maximum
$230K
Geographic Distribution
Officers & Directors
DS
David Spergel
4 yrs
Chairperson/Manager
Leadership
KM
Kelsey Martin
4 yrs
President/Manager
Leadership
ER
Euan Robertson
4 yrs
Vice President
Leadership
MK
Marlow Kee
8+ yrs
Treasurer/Manager
Leadership
BD
Brett Dakin
2 yrs
Secretary
Leadership
KM
Kelsey Martin
4 yrs
President/Manager
Leadership
DS
David Spergel
4 yrs
Chairperson/Manager
Leadership
ER
Euan Robertson
4 yrs
Secretary/Vice President
Leadership
MK
Marlow Kee
8+ yrs
Treasurer/Manager
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
BD
Brett Dakin
2 yrs
Secretary
Leadership
KM
Kelsey Martin
4 yrs
President/Manager
Leadership
DS
David Spergel
4 yrs
Chairperson/Manager
Leadership
MK
Marlow Kee
8+ yrs
Treasurer/Manager
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
ER
Euan Robertson
4 yrs
Manager
KM
Kelsey Martin
4 yrs
President/Manager
Leadership
MS
Marilyn H Simons
5 yrs
Chairperson/Manager
Leadership
DS
David Spergel
4 yrs
Chairperson/Manager
Leadership
JS
John Spiro
2 yrs
President/Manager
Leadership
MK
Marlow Kee
8+ yrs
Treasurer/Manager
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
ER
Euan Robertson
4 yrs
Manager
MS
Marilyn H Simons
5 yrs
Chairperson/Manager
Leadership
JS
John Spiro
2 yrs
President/Manager
Leadership
LR
Louis F Reichardt
4 yrs
President/Manager
Leadership
MK
Marlow Kee
8+ yrs
Treasurer
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
LR
Louis F Reichardt
4 yrs
President/Manager
Leadership
MS
Marilyn H Simons
5 yrs
Chairperson/Manager
Leadership
MK
Marlow Kee
8+ yrs
Treasurer
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
LR
Louis F Reichardt
4 yrs
President/Manager
Leadership
MS
Marilyn H Simons
5 yrs
Chairperson/Manager
Leadership
MK
Marlow Kee
8+ yrs
Treasurer
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
MS
Marilyn H Simons
5 yrs
Chairperson/Manager
Leadership
LR
Louis F Reichardt
4 yrs
President/Manager
Leadership
MK
Marlow Kee
8+ yrs
Treasurer
Leadership
MG
Marion Greenup
7 yrs
Secretary
Leadership
Grants Awarded (20 total)
| Purpose | ||||
|---|---|---|---|---|
| Massachusetts Institute of Technology | Cambridge, MA | $230,259 | Advancing a Biomarker of Reduced GABAergic Action in the Autistic Brain | 2017 |
| The Children'S Hospital of Philadelphia Research Institute | Philadelphia, PA | $200,000 | COMPUTER VISION BASED PHENOTYPING OF 16P11.2 ARBACLOFEN DOUBLE BLIND PLACEBO CONTROLLED STUDY. | 2024 |
| The Childrens Hospital of Philadelphia | Philadelphia, PA | $149,808 | MEG/MRS Dose Response Study of STX209 in ASD | 2017 |
| The Children'S Hospital of Philadelphia | Philadelphia, PA | $149,808 | MEG/MRS Dose Response Study of STX209 in ASD | 2017 |
| The Childrens Hospital of Philadelphia | Philadelphia, PA | $149,808 | MEG/MRS Dose Response Study of STX209 in ASD | 2018 |
| University of Washington | Seattle, WA | $124,722 | ELECTROPHYSIOLOGICAL INDICES OF NEURAL FUNCTION ASSOC. WITH ARBACLOFEN ADMIN. IN 16P11.2 | 2020 |
| The Children'S Hospital of Philadelphia Research Institute | Philadelphia, PA | $107,775 | COMPUTER VISION BASED PHENOTYPING OF 16P11.2 ARBACLOFEN DOUBLE BLIND PLACEBO CONTROLLED STUDY. | 2020 |
| The Regents of the University of California | Davis, CA | $87,646 | Preclinical evaluation of therapeutic efficacy of r-baclofen in reversing behavioral deficits in 16p11.2 deletion mice | 2017 |
| The Trustees of the University of Pennsylvania | Philadelphia, PA | $85,946 | Assessment of Arbaclofen treatment on habituation, cognition and repetitive motor behaviors in a mouse model of 16p... | 2017 |
| Institut De Genetique Et De Biologie Moleculaire | Illkirch, None | $77,741 | R-Baclo2: Retesting the Arbaclofen treatment on the Del(7Sult1a1-Spn)6Yah 16p11.2 deletion model | 2017 |
| King'S College London | London, None | $75,001 | GABAb in ASD. A high dose Arbaclofen fMRI and visual processing study. | 2017 |
| King'S College London | London, None | $74,999 | GABAb in ASD. A high dose Arbaclofen fMRI and visual processing study. | 2017 |
| King'S College London | London, None | $74,999 | GABAb in ASD. A high dose Arbaclofen fMRI and visual processing study. | 2018 |
| John Hopkins University School of Medicine | Baltimore, MD | $74,154 | Development of radiotracers for PET imaging of GABA-B receptors in non-human primates | 2017 |
| Harvard Medical School | Boston, MA | $59,875 | Using Motion Sequencing to Assess Behavioral Effects of Arbaclofen | 2017 |
| University of Washington | Seattle, WA | $44,758 | ELECTROPHYSIOLOGICAL INDICES OF NEURAL FUNCTION ASSOC. WITH ARBACLOFEN ADMIN. IN 16P11.2 | 2021 |
| Masachusetts Institute of Technology | Cambridge, MA | $39,084 | Advancing a Biomarker of Reduced GABAergic Action in the Autistic Brain | 2017 |
| Massachusetts Institute of Technology | Cambridge, MA | $39,084 | Advancing a Biomarker of Reduced GABAergic Action in the Autistic Brain | 2018 |
| Institut De Genetique Et De Biologie Moleculaire | Illkirch, None | $18,317 | R-Baclo2: Retesting the Arbaclofen treatment on the Del(7Sult1a1-Spn)6Yah 16p11.2 deletion model | 2017 |
| Institut De Genetique Et De Biologie Moleculaire | Illkirch, None | $18,317 | R-Baclo2: Retesting the Arbaclofen treatment on the Del(7Sult1a1-Spn)6Yah 16p11.2 deletion model | 2018 |